Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16582460 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL5543839 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL14621023 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL6281759 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23567378 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL6120008 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23567381 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL5327335 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL462832 | 0.98 | CASP2 (0.63) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL3310816 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581047-A1 | TOXIN-BINDER FOR HEMODIALYSIS | Universität Hamburg (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047073-A1 | TOXIN-BINDER FOR HEMODIALYSIS | UNIVERSITÄT HAMBURG (DE) | 2024-03-07 | — | — | WO | disclosed |
| WO-2021199082-A1 | ANTIMICROBIAL COMPOUNDS AND USES THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2021-10-07 | — | — | WO | disclosed |
| US-20150140588-A1 | Lipase Variants and Polynucleotides Encoding Same | NOVOZYMES A/S (DK) | 2015-05-21 | — | — | US | disclosed |
| CN-103827298-A | Lipase variants and polynucleotides encoding same | NOVOZYMES AS | 2014-05-28 | — | — | CN | disclosed |
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| EP-1689714-A2 | THERAPEUTIC USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054198-A2 | THERAPEUTICS USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105810-A1 | THERAPEUTICS | RYR1, ATP2A1, CACNA1E | CASP2 1851/4885NAAA 770/4885EPHX1 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.